Literature DB >> 4127547

Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay.

Y B Gordon, M J Martin, A T McNeile, T Chard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4127547     DOI: 10.1016/s0140-6736(73)92937-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Monitoring the fetoplacental unit. The placenta.

Authors:  T Chard
Journal:  Postgrad Med J       Date:  1975-04       Impact factor: 2.401

2.  Conditions for collection of serum samples for the measurement of fibrin(ogen) degradation products by radioimmunoassay of fragment E.

Authors:  M J Martin; Y B Gordon; S M Ratky; L R Baker; T Chard
Journal:  J Clin Pathol       Date:  1976-04       Impact factor: 3.411

3.  Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?

Authors:  R S Maurice-Williams
Journal:  Br Med J       Date:  1978-04-15

4.  Fibrin(ogen)olysis in polymyalgia rheumatica and temporal arteritis: preliminary findings on association with disease activity.

Authors:  R G Grau; S S Kassan; J J Franks; H Kaplan; S H Walker; E M Tan
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

5.  Urinary fibrin-fibrinogen degradation products in nephrotic syndrome.

Authors:  C L Hall; N Pejhan; J M Terry; J D Blainey
Journal:  Br Med J       Date:  1975-02-22

6.  Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?

Authors:  R S Maurice-Williams; Y B Gordon; A Sykes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-02       Impact factor: 10.154

7.  Levels of fibrinogen/fibrin degradation fragment E and related substances in sera and effusions of patients with malignant disease.

Authors:  Z Gilead; R Zahavi; A Hatzubai; G Brufman; S Biran; D Sulitzeanu
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.